Biogen Idec Inc

More

• Final Glance: Biotechnology companies Thursday, 23 May 2013 | 6:03 PM ET

  Amgen Inc. rose $1.09 or 1.0 percent, to $105.62. Biogen Idec fell$. 45 or. 2 percent, to $232.62. Gilead Sciences Inc. fell$. 45 or. 8 percent, to $55.48.

• Midday Glance: Biotechnology companies Thursday, 23 May 2013 | 1:46 PM ET

  Amgen Inc. rose $1.32 or 1.3 percent, to $105.85. Biogen Idec rose$. 79 or. 3 percent, to $233.86. Celgene Corp. rose $1.03 or. 8 percent, to $124.47.

• Alkermes posts 4Q profit as royalty payments rise Thursday, 23 May 2013 | 12:44 PM ET

  NEW YORK-- Alkermes PLC said Thursday that it was profitable in its fiscal fourth quarter as it received bigger royalty payments and more revenue for drug manufacturing. Alkermes said it earned $3 million, or 2 cents per share, over the three months ended March 31.

• Early Glance: Biotechnology companies Thursday, 23 May 2013 | 10:45 AM ET

  Amgen Inc. fell$. 78 or. 7 percent, to $103.75. Biogen Idec fell $4.46 or 1.9 percent, to $228.61. Celgene Corp. fell $2.11 or 1.7 percent, to $121.33.

• Final Glance: Biotechnology companies Wednesday, 22 May 2013 | 6:07 PM ET

  Amgen Inc. rose$. 29 or. 3 percent, to $104.53. Biogen Idec rose $1.74 or. 8 percent, to $233.07. Celgene Corp. fell$. 06 or percent, to $123.44.

• Midday Glance: Biotechnology companies Wednesday, 22 May 2013 | 1:17 PM ET

  Amgen Inc. rose $1.86 or 1.8 percent, to $106.10. Biogen Idec rose $4.67 or 2.0 percent, to $236.00. Celgene Corp. rose $2.58 or 2.1 percent, to $126.08.

• Early Glance: Biotechnology companies Wednesday, 22 May 2013 | 10:50 AM ET

  Amgen Inc. rose $1.92 or 1.8 percent, to $106.16. Biogen Idec rose $5.38 or 2.3 percent, to $236.71. Celgene Corp. rose $4.10 or 3.3 percent, to $127.60.

• Final Glance: Biotechnology companies Tuesday, 21 May 2013 | 8:50 PM ET

  Amgen Inc. rose $2.06 or 2.0 percent, to $104.24. Biogen Idec rose $6.15 or 2.7 percent, to $231.33. Celgene Corp. rose$. 38 or. 3 percent, to $123.50.

• Biogen submits new MS drug for FDA approval Tuesday, 21 May 2013 | 3:13 PM ET

  WESTON, Mass.-- Specialty drugmaker Biogen Idec said Tuesday it submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval. The company also plans to submit the drug to the European Medicines Agency in coming weeks. Shares of Biogen Idec Inc. rose $6.15, or 2.7 percent, to close Tuesday at $231.33.

• Midday Glance: Biotechnology companies Tuesday, 21 May 2013 | 1:16 PM ET

  Amgen Inc. rose $1.72 or 1.7 percent, to $103.90. Biogen Idec rose $6.90 or 3.1 percent, to $232.08. Celgene Corp. fell$. 27 or. 2 percent, to $122.85.

• Early Glance: Biotechnology companies Tuesday, 21 May 2013 | 10:36 AM ET

  Amgen Inc. rose $2.04 or 2.0 percent, to $104.22. Biogen Idec rose $5.56 or 2.5 percent, to $230.74. Celgene Corp. rose $1.03 or. 8 percent, to $124.15.

• Final Glance: Biotechnology companies Monday, 20 May 2013 | 6:04 PM ET

  Amgen Inc. fell $3.45 or 3.3 percent, to $102.18. Biogen Idec fell $1.67 or. 7 percent, to $225.18. Celgene Corp. fell $1.79 or 1.4 percent, to $123.12.

• UPDATE 3-Royalty raises Elan bid, issues ultimatum to shareholders Monday, 20 May 2013 | 3:27 PM ET

  *Bid raised to $12.50/ share from $11.25. DUBLIN/ NEW YORK, May 20- Royalty Pharma raised its hostile bid for Elan to $12.50 per share and threatened to withdraw the bid if Elan shareholders approve a series of defensive transactions announced by the Irish drug firm. Royalty previously offered $11.25 a share.

• UPDATE 2-Royalty ups Elan bid and issues shareholder ultimatum Monday, 20 May 2013 | 1:43 PM ET

  DUBLIN, May 20- Royalty Pharma raised its hostile bid for Elan to $12.50 per share and heaped pressure on shareholders, saying it will withdraw the bid if they approve a series of defensive transactions announced by the Irish drug firm.

• Midday Glance: Biotechnology companies Monday, 20 May 2013 | 1:16 PM ET

  Amgen Inc. fell $3.37 or 3.2 percent, to $102.26. Biogen Idec fell$. 36 or. 2 percent, to $226.49. Celgene Corp. fell $1.18 or. 9 percent, to $123.73.

• Early Glance: Biotechnology companies Monday, 20 May 2013 | 10:31 AM ET

  Amgen Inc. fell $1.36 or 1.3 percent, to $104.28. Biogen Idec rose $5.05 or 2.2 percent, to $231.90. Celgene Corp. fell$. 33 or. 3 percent, to $124.58.

• UPDATE 1-Elan strikes more deals to repel Royalty bid Monday, 20 May 2013 | 5:17 AM ET

  DUBLIN, May 20- Elan announced its second major drug deal inside a week on Monday and said it would buy back more shares as it continues to bat against a $5.7 billion takeover bid from U.S. investor Royalty Pharma.

• Final Glance: Biotechnology companies Friday, 17 May 2013 | 6:03 PM ET

  Amgen Inc. rose$. 66 or. 6 percent, to $105.63. Biogen Idec fell $1.14 or. 5 percent, to $226.85. Celgene Corp. rose $1.43 or 1.2 percent, to $124.91.

• Midday Glance: Biotechnology companies Friday, 17 May 2013 | 1:32 PM ET

  Amgen Inc. fell$. 13 or. 1 percent, to $104.84. Biogen Idec fell $3.07 or 1.3 percent, to $224.92. Celgene Corp. fell$. 34 or. 3 percent, to $123.14.

• Early Glance: Biotechnology companies Friday, 17 May 2013 | 10:25 AM ET

  Amgen Inc. rose$. 64 or. 6 percent, to $105.61. Biogen Idec fell $1.82 or. 8 percent, to $226.17. Celgene Corp. rose$. 43 or. 3 percent, to $123.91.